NEX-I
Latest round
- Series B
Last raised
- Aug 2025
Total raised
- $60M
Investors
- 21
About NEX-I
, trading under the name NEX-I, is a bio venture and next-generation immunotherapy drug development company that specializes in immuno-cancer drugs that increase the response rate by discovering refractory inducing factors. The company is conducting research on drug administration to cancer patients who do not respond to immunotherapy with the goal to overcome the limitation of the low response rate of existing immunotherapy. In May 2026, NEX-I, Inc.S. NEX-I, Inc. offers immuno-cancer drugs.
Who invested in NEX-I
21 investors across 3 rounds
See all investors in NEX-I
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about NEX-I
Who invested in NEX-I?
NEX-I has 21 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has NEX-I raised?
NEX-I has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did NEX-I last raise money?
NEX-I's most recent round on record is a Series B, in Aug 2025.
What does NEX-I do?
, trading under the name NEX-I, is a bio venture and next-generation immunotherapy drug development company that specializes in immuno-cancer drugs that increase the response rate by discovering refractory inducing factors.
Where is NEX-I headquartered?
NEX-I is headquartered in Seoul, South Korea.
Which VCs invest in companies like NEX-I?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Yufu Capital, ICBC Capital Management and Ningbo Tongshang Fund back healthcare specialists companies at NEX-I's stage. Their profiles are linked below.
VCs backing healthcare specialists startups at Series B
Raising like NEX-I? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.